Anti-Angiogenesis Drug Discovery and Development

Anti-Angiogenesis Drug Discovery and Development

Volume: 5

The inhibition of angiogenesis is an effective mechanism of slowing down tumor growth and malignancies. The process of induction or pro-angiogenesis is highly desirable for the treatment of ...
[view complete introduction]

US $
30

*(Excluding Mailing and Handling)



Angiogenesis and Chromene-based Antiangiogenic Therapeutic Agents

Pp. 151-188 (38)

Olivia Pontes, Ana Raquel-Cunha, Sofia Oliveira-Pinto, Fatima Baltazar, Olga Martinho and Marta Costa

Abstract

Tumor vascularization plays an essential role in cancer progression. Tumor vasculature provides oxygen and nutrients to cancer cells and removes waste products which is important for the rapid growth of tumors. Importantly, the tumor associated vessels are also used for tumor cell metastization, in which cancer cells invade distant organs. Therefore, inhibition of angiogenesis constitutes one of the elected targeted approaches for cancer treatment.

The first FDA approved antiangiogenic drug was bevacizumab, an antibody against vascular endothelial growth factor (VEGF) that has been used to treat metastatic tumors. However, despite the initial increase in survival rates, no major benefit in global survival was described and patients ended up relapsing due to acquired resistance. Further, monotherapy with this type of agents is not generally associated with improvement of survival, being antiangiogenic therapy a strategy that is worth pursuing as combination therapy. Thus, the efficacy of angiogenesis inhibitors is still a major challenge.

Several families of naturally occurring compounds have been described as antiangiogenic agents with promising results, such as stilbenes, chalcones, terpenoids, phenylethanoids and others. Due to their remarkable structure variety, plant polyphenols have been extensively studied and found to inhibit angiogenesis and metastasis through the regulation of multiple signaling pathways involved in cancer development. Chromenes and coumarins, such as crolibulin (EPC2407), have already been identified as vascular disrupting agents with promising antiangiogenic properties. The substitution pattern highly influences the activity and mode of action in various types of cancer. Specifically, chromenes are found to regulate the expression of VEGF, matrix metalloproteinases (MMPs) and receptor tyrosine kinases RTKs (e.g. EGFR) signaling pathways.

This chapter focuses on the antiangiogenic properties of chromenes, coumarins and derivatives, highlighting the recent progress in drug development and clinical applications.

Keywords:

Angiogenesis, Antiangiogenic agents, Cancer, Chromenes.

Affiliation:

Life and Health Sciences Research Institute (ICVS), University of Minho, Campus of Gualtar, Braga, Portugal.